Los Angeles Clinical Trials

Recent papers from Los Angeles Clinical Trials

1. A Phase I Clinical Trial of Chemoimmunotherapy with Alternating Intravesical Gemcitabine and Bacillus Calmette-Guérin (GemBCG) for BCG-Exposed High-Grade Non-Muscle-Invasive Bladder CancerThe Journal of Urology · 2026
2. Trials Terminated EarlyJAMA · 2026
3. Less Invasive Rapid Tranquilization in LMIC Emergency Settings: Comparison of Oral Risperidone Plus Clonazepam Versus Intramuscular Haloperidol in a Randomized TrialInternational Journal of Social Psychiatry · 2026
4. Splenic neuromodulation as monotherapy and in combination with biologic or targeted synthetic DMARDs for difficult-to-treat rheumatoid arthritis (ConsiderRAte): a randomised, sham-controlled, early feasibility trialEClinicalMedicine · 2026
5. A Multicenter, Prospective, Randomized, Subject Blinded Comparative Study of Axoguard Nerve Cap® and Neurectomy for the Treatment of Symptomatic Neuroma and Prevention of Recurrent End-Neuroma Pain (REPOSE)The Journal of Foot & Ankle Surgery · 2026
6. Smartphone Application-mediated, Supervised, At-home Telespirometry Identifies Statistically Significant Differences in Erect and Supine Slow Vital Capacity and ALSFRS-R Decline as a Function of Non-invasive Ventilation Treatment Status in Multicenter, Prospective, Longitudinal, Observational Clinical Study [NCT05106569] (P7-7.002)Neurology · 2026
7. Historical Initiatives Characterizing French – Japanese Treatment Development for 19th Century Bubonic Plague (BP) and 20th–21st Century Amyotrophic Lateral Sclerosis (ALS) (P8-20.005)Neurology · 2026
8. Sodium-Glucose Co-Transporter 2 Inhibitor Use and Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis and Type 2 Diabetes: A Retrospective Observational Cohort Study Using Real-World DataJournal of Clinical Medicine Research · 2026
9. INCA033890-303: A randomized, double-blind, phase 3 study of FOLFOX and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite-stable colorectal cancer.Journal of Clinical Oncology · 2026
10. A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 T-cell engager in participants with advanced or metastatic microsatellite-stable (MSS)/microsatellite instability–low (MSI-L) colorectal cancer (CRC).Journal of Clinical Oncology · 2026
11. A randomized, active-controlled phase 3 study of ivonescimab + FOLFOX versus bevacizumab + FOLFOX as first-line treatment of metastatic colorectal cancer (mCRC): HARMONi-GI3.Journal of Clinical Oncology · 2026
12. Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid.Journal of Clinical Oncology · 2026
13. Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutations.Journal of Clinical Oncology · 2026
14. Ivonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase 2 study.Journal of Clinical Oncology · 2026
15. Zongertinib combined with T-DXd in HER2-positive metastatic gastric, gastroesophageal junction, or esophageal carcinoma (mGEAC): First results from a phase Ib/II dose-escalation trial.Journal of Clinical Oncology · 2026
16. Perspectives of Information Access in the Informed Consent Process for Clinical Research Participation in AustraliaEthics & Human Research · 2026
17. Cardiac Damage and Quality of Life After Aortic Valve Replacement in the PARTNER TrialsJournal of the American College of Cardiology · 2023
18. (160) Safety and Pharmacokinetics of Mk-8527 Oral Once-Monthly: A Phase 2 Study in Adults at Low Risk of HIV-1 ExposureThe Journal of Sexual Medicine · 2026
19. General practice follow-up after hospital discharge in older adults: Retrospective records analysisBritish Journal of General Practice · 2026
20. Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid TumorsCancer Research Communications · 2026